This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
by Zacks Equity Research
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
JNJNegative Net Change INCYNegative Net Change NVSNegative Net Change ABBVNegative Net Change
biotechs
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
BIIBNegative Net Change JNJNegative Net Change ALXNPositive Net Change INCYNegative Net Change ARGXPositive Net Change
biotechs pharmaceuticals
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
by Zacks Equity Research
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
GSKNegative Net Change RGENNegative Net Change BLPHPositive Net Change VBIVPositive Net Change
biotechs
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
by Zacks Equity Research
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
ARNAPositive Net Change RGENNegative Net Change BLPHPositive Net Change
biotechs
Moving Average Crossover Alert: Veracyte (VCYT)
by Zacks Equity Research
Veracyte (VCYT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
VCYTNegative Net Change
biotechs medical
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
ALXNPositive Net Change RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
by Zacks Equity Research
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
by Zacks Equity Research
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
JNJNegative Net Change RHHBYNegative Net Change ABBVNegative Net Change ARGXPositive Net Change
biotechs
Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab
by Zacks Equity Research
FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
BIIBNegative Net Change RHHBYNegative Net Change NVSNegative Net Change AMGNPositive Net Change
biotechs
Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens
by Zacks Equity Research
Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
BIIBNegative Net Change LLYNegative Net Change XBINegative Net Change BBCNegative Net Change SBIONegative Net Change PBENegative Net Change GNOMNegative Net Change
biotechs etfs
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
BIIBNegative Net Change AZNNegative Net Change LLYNegative Net Change NVSNegative Net Change AMGNPositive Net Change ANVSPositive Net Change SAVAPositive Net Change
biotechs pharmaceuticals
Biogen's Alzheimer Drug Wins FDA Approval
by Mark Vickery
Biogen closed the day up 38% but had been up as much as 60% on the news, and this came after a brief halt in share trading.
BIIBNegative Net Change IBBNegative Net Change SFIXNegative Net Change
biotechs
Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
by Zacks Equity Research
Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.
NVSNegative Net Change BAYRYNegative Net Change OMERNegative Net Change
biotechs pharmaceuticals
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
by Zacks Equity Research
Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
BLPHPositive Net Change LEGNNegative Net Change CGEMNegative Net Change
biotechs
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.
ADPTPositive Net Change XNCRNegative Net Change ORGOPositive Net Change
biotechs
Constellation (CNST) Surges on Takeover Deal With MorphoSys
by Zacks Equity Research
Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.
INCYNegative Net Change RPRXNegative Net Change MORPositive Net Change CNSTPositive Net Change
biotechs
Stock Market News for Jun 3, 2021
by Zacks Equity Research
Wall Street closed marginally higher on Wednesday.
MRNANegative Net Change
biotechs
Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.
RHHBYNegative Net Change MRKNegative Net Change BMYNegative Net Change RGENNegative Net Change
biotechs
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
BIIBNegative Net Change ALKSNegative Net Change PFENegative Net Change MRNANegative Net Change MYOVPositive Net Change CVACNegative Net Change
biotechs
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
JNJNegative Net Change ALXNPositive Net Change RGENNegative Net Change IMVTPositive Net Change
biotechs
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
by Zacks Equity Research
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
JNJNegative Net Change ALKSNegative Net Change AZNNegative Net Change ABBVNegative Net Change
biotechs
Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.
PFENegative Net Change MRNANegative Net Change TMONegative Net Change BNTXNegative Net Change
biotechs
Find Strong Stocks with this First Profit Screener
by Benjamin Rains
The Zacks 'First Profit' screener is a solid place to start searching for strong stocks...
MRNANegative Net Change CHWYPositive Net Change
biotechs consumer-staples earnings industrial-products
Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?
by Zacks Equity Research
Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change LLYNegative Net Change
biotechs pharmaceuticals